• +971551792927
  • info-ucg@utilitarianconferences.com
Login
WhatsApp

Track 41: Microbiota

Related Sessions

Track 1: Endoscopy


Endoscopy is a medical procedure that allows healthcare providers to examine the...

Track 2: GI (Gastrointestinal)

The gastrointestinal (GI) system, also known as the digestive system, is a complex...

Track 41: Microbiota

Track 41: Microbiota

Introduction

The human microbiota, comprising trillions of microorganisms living in and on the body, plays a critical role in maintaining health and influencing disease progression. Recent research has uncovered the dynamic interactions between the gut microbiome, host immunity, metabolism, and even neurological functions. Track 41: Microbiota will spotlight these exciting developments and their clinical implications.

Microbiota and Gut Health

This session will explore the complex relationship between the gut microbiota and gastrointestinal health. Discussions will highlight how microbial balance affects digestion, absorption, and intestinal immunity, while also addressing conditions such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and colorectal cancer.

Microbiota Beyond the Gut

Beyond digestion, the microbiota influences multiple body systems, including the brain, liver, lungs, and skin. Experts will present evidence on the gut-brain axis, the role of the microbiome in metabolic syndromes like obesity and diabetes, and its impact on immune-mediated diseases.

Advances in Microbiome Research & Therapeutics

This segment will focus on cutting-edge microbiome-based diagnostics and therapies. Key topics will include the application of next-generation sequencing, metabolomics, and bioinformatics in microbiome analysis, as well as novel therapeutic approaches such as fecal microbiota transplantation (FMT), probiotics, prebiotics, and postbiotics.

Clinical and Translational Perspectives

Clinicians and researchers will share insights into how microbiome science is being translated into real-world practice. Case studies, ongoing clinical trials, and personalized microbiome-based interventions will be discussed to bridge the gap between research and patient care.

Conclusion

Track 41 will provide a comprehensive platform for understanding the microbiota’s expanding role in human health and disease. By integrating basic science, clinical research, and therapeutic innovations, this track promises to advance knowledge and foster collaborations in the rapidly evolving field of microbiome science.